Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-26T08:47:18.562Z Has data issue: false hasContentIssue false
  • English
  • Français

Orally disintegrating olanzapine tablets in the treatment of a neuropsychiatric patient with dysphagia

Published online by Cambridge University Press:  24 June 2014

Hui-Yi Wang  and
Nian-Sheng Tzeng
Hui-Yi Wang
Affiliation:
Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan
Nian-Sheng Tzeng*
Affiliation:
Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan School of Medicine, National Defense Medical Center, Taipei, Taiwan
*
Nian-Sheng Tzeng, MD Department of Psychiatry, Tri-Service General Hospital, #325, Sec. 2, Chenggong Road, Nei-Hu District, Taipei 114, Taiwan. Tel.: 886 2 87923311; Fax: 886 2 87927221; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Comment & Critique
Information
Acta Neuropsychiatrica , Volume 23 , Issue 1 , February 2011 , pp. 53 - 54
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Sajatovic, M, Valenstein, M, Blow, FC, Ganoczy, D, Ignacio, RV.Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8:232–241.CrossRefGoogle ScholarPubMed
2.Gilmer, TP, Dolder, CR, Lacro, JP et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692–699.Google Scholar
3.Freudenreich, O.Treatment noncompliance with orally disintegrating olanzapine tablets. Can J Psychiatry 2003;48:353–354.CrossRefGoogle ScholarPubMed
4.Citrome, L.Re: treatment noncompliance with orally disintegrating olanzapinetablets. Can J Psychiatry 2004;49:412–413 (author reply 413).CrossRefGoogle Scholar
5.Javle, M, Ailawadh, S, Yang, GY, Nwogu, CE, Schiff, MD, Nava, HR.Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol 2006;4: 365–373,379.Google ScholarPubMed
6.San, L, Casillas, M, Ciudad, A, Gilaberte, I.Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther 2008;14:203–214.CrossRefGoogle ScholarPubMed
7.Davis, JM, Chen, N.The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62:757–771.CrossRefGoogle ScholarPubMed
8.Tohen, M, Greil, W, Calabrese, JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281–1290.CrossRefGoogle ScholarPubMed
9.Markowitz, JS, DeVane, CL, Malcolm, RJ, Gefroh, HA, Wang, JS, Zhu Donovan, JL.Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2006;46:164–171.CrossRefGoogle ScholarPubMed
10.Breitbart, W, Tremblay, A, Gibson, C.An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002;43:175–182.Google Scholar
11.Shen, YC, Lee, MY, Lin, CC, Chen, CH.Orally disintegrating olanzapine for the treatment of a manic patient with esophageal stricture plus chronic pharangitis. Prog Neuro Psychopharmacol Biol Psychiatr 2007;31:541–542.Google Scholar
12.Douzenis, A, Michopoulos, I, Economopoulos, T, Lykouras, L, Soldatos, CR.Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition. Eur J Cancer Care 2007;16:289–290.CrossRefGoogle Scholar